Investors Buy Shares of Merck & Company, Inc. (MRK) on Weakness

Traders bought shares of Merck & Company, Inc. (NYSE:MRK) on weakness during trading on Tuesday. $147.76 million flowed into the stock on the tick-up and $92.56 million flowed out of the stock on the tick-down, for a money net flow of $55.20 million into the stock. Of all equities tracked, Merck & had the 12th highest net in-flow for the day. Merck & traded down ($0.11) for the day and closed at $54.99

A number of research analysts recently issued reports on the company. upgraded Merck & from a “reduce” rating to a “hold” rating in a research report on Wednesday, August 9th. BidaskClub lowered Merck & from a “hold” rating to a “sell” rating in a research report on Wednesday, August 9th. UBS AG reduced their price objective on Merck & from $72.00 to $67.00 and set a “buy” rating for the company in a research report on Monday, October 30th. Barclays PLC downgraded Merck & from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $72.00 to $62.00 in a research note on Monday, October 30th. Finally, Cowen and Company reaffirmed a “hold” rating and set a $70.00 target price on shares of Merck & in a research note on Friday, November 3rd. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the stock. Merck & presently has a consensus rating of “Hold” and an average target price of $67.07.

The company has a quick ratio of 1.16, a current ratio of 1.43 and a debt-to-equity ratio of 0.57. The firm has a market capitalization of $151,151.77, a P/E ratio of 14.26, a P/E/G ratio of 2.39 and a beta of 0.78.

Merck & (NYSE:MRK) last announced its earnings results on Friday, October 27th. The company reported $1.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.03 by $0.08. The company had revenue of $10.33 billion for the quarter, compared to analyst estimates of $10.54 billion. Merck & had a return on equity of 27.08% and a net margin of 11.60%. Merck &’s revenue for the quarter was down 2.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.07 earnings per share. analysts forecast that Merck & Company, Inc. will post 3.95 EPS for the current year.

In other news, Director Thomas H. Glocer sold 5,000 shares of the business’s stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $56.20, for a total transaction of $281,000.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.25% of the stock is owned by insiders.

Several institutional investors have recently made changes to their positions in MRK. Janus Henderson Group PLC raised its position in shares of Merck & by 172.3% during the third quarter. Janus Henderson Group PLC now owns 6,705,564 shares of the company’s stock worth $429,347,000 after purchasing an additional 4,243,246 shares during the period. Capital International Investors raised its position in shares of Merck & by 55.3% during the third quarter. Capital International Investors now owns 9,623,382 shares of the company’s stock worth $616,185,000 after purchasing an additional 3,428,400 shares during the period. Vanguard Group Inc. raised its position in shares of Merck & by 1.7% during the second quarter. Vanguard Group Inc. now owns 194,144,317 shares of the company’s stock worth $12,442,709,000 after purchasing an additional 3,312,459 shares during the period. Stifel Financial Corp raised its position in shares of Merck & by 95,700.4% during the third quarter. Stifel Financial Corp now owns 3,281,163 shares of the company’s stock worth $210,016,000 after purchasing an additional 3,277,738 shares during the period. Finally, Amundi Pioneer Asset Management Inc. raised its position in shares of Merck & by 415.5% during the third quarter. Amundi Pioneer Asset Management Inc. now owns 3,560,465 shares of the company’s stock worth $227,977,000 after purchasing an additional 2,869,844 shares during the period. 73.15% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Markets Daily and is the sole property of of Markets Daily. If you are accessing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece can be viewed at https://www.themarketsdaily.com/2017/11/15/investors-buy-shares-of-merck-company-inc-mrk-on-weakness.html.

About Merck &

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply